Cellular Logistics is a developer of an acellular biomaterial designed to significantly increase cell survival rates and retention of regenerative medicine therapeutics
Cell therapies for damaged heart tissue often have poor cell retention, survival and integration after delivery.
R&D Focus
Cardiac extracellular matrix, cell-retention biomaterials and regenerative medicine.
Innovative Solution
CFX is an acellular cardiac fibroblast-derived matrix designed to improve the local environment for cell survival and tissue repair.
Solution Effectiveness
Preclinical studies reported by the company show improved cell retention, remuscularization and cardiac function; clinical effectiveness has not yet been established.
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$1.37M
Last Funding Date
5/30/2023
Startup Stage
Early Stage
Lead Investors
National Institutes of Health, Lawrence University, Wisconsin Technology Innovation Initiative, Discovery to Product
People
Founders
Eric Schmuck
Amish Raval
Peiman Hematti
CEO
Alex Vodenlich
About
Cellular Logistics is a developer of an acellular biomaterial designed to significantly increase cell survival rates and retention of regenerative medicine therapeutics
Products
Product
CFX cardiac regenerative biomaterial platform.
Star Product
CFX, because it is the company’s lead matrix for improving cardiac cell-therapy outcomes.
Demo Product or Complete Product?
Preclinical development moving toward clinical trials.
Future Plan
Investment Funding
Announced new NIH-backed and investor funding in 2026 to move CFX toward clinical studies.
M&A and Collabs
Collab
Academic cardiac-research groups: preclinical validation and mechanism studies.
Collab
NIH-backed programs: development toward clinical trials.
Something missing or incorrect on this page? Help us enrich this information
